186 related articles for article (PubMed ID: 15718416)
1. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Dunleavy K; Hakim F; Kim HK; Janik JE; Grant N; Nakayama T; White T; Wright G; Kwak L; Gress R; Tosato G; Wilson WH
Blood; 2005 Aug; 106(3):795-802. PubMed ID: 15718416
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia associated with rituximab therapy.
Grant C; Wilson WH; Dunleavy K
Curr Opin Hematol; 2011 Jan; 18(1):49-54. PubMed ID: 21102324
[TBL] [Abstract][Full Text] [Related]
3. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Terrier B; Ittah M; Tourneur L; Louache F; Soumelis V; Lavie F; Casadevall N; Candon S; Hummel A; Mariette X; Buzyn A
Haematologica; 2007 Feb; 92(2):e20-3. PubMed ID: 17405749
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-associated neutropenia.
Dunleavy K; Tay K; Wilson WH
Semin Hematol; 2010 Apr; 47(2):180-6. PubMed ID: 20350665
[TBL] [Abstract][Full Text] [Related]
5. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M
Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695
[TBL] [Abstract][Full Text] [Related]
6. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Wolach O; Bairey O; Lahav M
Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
9. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
Arai Y; Yamashita K; Mizugishi K; Nishikori M; Hishizawa M; Kondo T; Kitano T; Kawabata H; Kadowaki N; Takaori-Kondo A
Hematology; 2015 May; 20(4):196-202. PubMed ID: 25130775
[TBL] [Abstract][Full Text] [Related]
11. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
12. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
Tesfa D; Gelius T; Sander B; Kimby E; Fadeel B; Palmblad J; Hägglund H
Med Oncol; 2008; 25(4):374-9. PubMed ID: 18278570
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
14. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
[TBL] [Abstract][Full Text] [Related]
16. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.
Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML
Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Khouri IF; Saliba RM; Hosing C; Okoroji GJ; Acholonu S; Anderlini P; Couriel D; De Lima M; Donato ML; Fayad L; Giralt S; Jones R; Korbling M; Maadani F; Manning JT; Pro B; Shpall E; Younes A; McLaughlin P; Champlin RE
J Clin Oncol; 2005 Apr; 23(10):2240-7. PubMed ID: 15800314
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
[TBL] [Abstract][Full Text] [Related]
20. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Rozman S; Sonc M; Novakovic BJ
Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
